Catalyst Health Ventures
VC Fund
Braintree, United States
Catalyst Health Ventures is an early-stage venture capital firm targeting technology solutions applied within the health care and life science industries. At the core of this strategy is a committed, hands-on approach to working with management and syndicate partners to build successful companies. Their disciplined investment process leverages bothintellectual and financial capital to originate deals, cultivate opportunities, and realize the full potential of emerging ventures in the health care and life science marketplace. We seek to invest in companies addressing major global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. We invest in pioneering and proprietary technological solutions fundamentally designed to reduce treatment costs and improve patient outcomes. By investing in solutions which have a technological foundation of engineering and development such as medical devices, diagnostic tools and instrumentation and consumer healthcare, we minimize the risks related to uncertain scientific experimentation.
- Total investments:
- 49
- Last investment:
- Lead investor:
- 51%
- Fund size:
- $1.1M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Catalyst Health Ventures invests in
Stages Catalyst Health Ventures invests in
Countries Catalyst Health Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.4M–$19M
- Series B
- $2.3M–$33M
- Series C
- $1.3M–$85M
Investment Focus
Industry
- Health Care 15 (31%)
- Medical Device 15 (31%)
- Biotechnology 10 (20%)
- Medical 9 (18%)
- Health Diagnostics 4 (8%)
Stage
- Series B 16 (33%)
- Series A 12 (24%)
- Series C 6 (12%)
- Seed 3 (6%)
- Series D 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Darshana Zaveri
Managing Partner
|
Managing Partner | Total investments: 24 | Find email | |
David Mackey
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Joshua Phillips
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
Joshua S. Phillips
Managing Partner
|
Managing Partner | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection. | $26M / Series B / Jul 28, 2026 | ||
| Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $25M / Venture - Series Unknown / Jun 16, 2026 | ||
| Text-based Health Assistant for patients. With Lena, clinics can offer callers the option to skip the long call queues and schedule their appointment via SMS-text live chat. Value-based care organizations and payers can offer members a text-based assistant that can take care of health tasks such as scheduling appointments and coordinating theircare. | $2M / Seed / Apr 22, 2025 | ||
| Esperto Medical is an Irvine, CA-based medical device company developing next-generation wearable diagnostics that enable hospital-based and remote patient monitoring with unprecedented ease and accuracy. Its unique resonance sonomanometry technology uses acoustic stimulation to directly and noninvasively measure continuous blood pressure withoutcalibration. | Series A / Oct 24, 2024 | ||
| Venova Medical develops vascular access systems for patients requiring renal replacement therapy. It addresses patient level and system barriers for access creation while simultaneously providing quickly functioning access with less need for intervention. The company was founded in 2018 and is headquartered in Los Gatos, California. | $30M / Series B / Sep 04, 2024 | ||
| Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for pain treatment. Backed by deep research, the company addresses crucial unmet needs in pain management, which has historically been dominated by systemic medicine. Brixton Biosciences' innovative therapeutics, such as its novel Neural Ice™, provide painrelief in a single, safe, and easy drug-free injectable that is a non-addictive, locally targeted, and comparatively long-lasting solution. | $33M / Series B / May 14, 2024 | ||
| AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. | $28M / Series C / Apr 24, 2024 | ||
| Avive Solutions develops a next-generation Automated External Defibrillator (AED) and software solutions. Avive's AED enables anyone to positively impact the outcome of a Sudden Cardiac Arrest (SCA) rescue by building a more robust solution that addresses the problem of SCA in its entirety. The AED will remove barriers to respond to a SCAscenario. It will be easy to purchase, easy to access in an emergency, easy to keep maintained, and most importantly easy to use effectively when it matters most.Avive Solutions is headquartered in San Francisco, California. | $56.5M / Series B / Feb 14, 2024 | ||
| Instylla’s focus is to leverage hydrogel technology . | $30M / Series C / Aug 15, 2023 | ||
| Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $26.3M / Series B / Dec 07, 2022 | ||
| See all 49 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Catalyst Health Ventures invest in?
Catalyst Health Ventures invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series B and Series A stage. Most of the 49 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Catalyst Health Ventures's check size?
Catalyst Health Ventures typically joins rounds of $1.4M–$19M at Series A, $2.3M–$33M at Series B and $1.3M–$85M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Catalyst Health Ventures participates in.
How do I contact Catalyst Health Ventures?
Public channels for Catalyst Health Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Catalyst Health Ventures?
The team at Catalyst Health Ventures includes Darshana Zaveri (Managing Partner), David Mackey (Chief Financial Officer) and Joshua Phillips (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
